Early Access — free while we kick the tires
EdgarHawk

GADICKE ANSBERT

10% Owner

10% Owner
2 filings analyzed · 2 companies · Latest 2026-01-14

Companies

Company Buys Sells Direction
Aktis Oncology, Inc. AKTS 4 0 Net buying
iTeos Therapeutics, Inc. ITOS 0 1 Net selling

Activity

January 2026
2026-01-14 Aktis Oncology, Inc. AKTS
high
Buy
1,112,777 shares
$20,029,986
Significance 7/10

10% Owner Gadicke Ansbert buys 1,112,777 shares (1.11M) of AKTS at $18.00 for $20,029,986; 5-insider cluster buy within 14 days

Gadicke Ansbert, a 10% owner, purchased 1,112,777 shares at $18.00 on 2026-01-12, increasing his holdings from 9,147,287 shares to 10,260,064 shares (+12.2% vs pre-transaction holdings). This transaction occurred at $18.00, 13.5% below the current market price of $20.81 just two trading days later, though AKTS only listed 4 trading days ago and 52-week metrics lack meaningful context. A cluster pattern shows 5 other insiders also bought within the past 14 days, suggesting coordinated accumulation by the insider cohort. The derivative-conversion flagged for this filing indicates this purchase may represent a conversion or exercise of derivative securities; the insider's full position includes securities in Form 4 Table II (not yet populated), so reported holdings should not be interpreted as a total position statement. The concentration of concurrent insider buying and the substantial purchase volume by a major shareholder warrants investor attention to the underlying conviction or signaling intent in the early trading window post-IPO.

May 2025
high
Sell
1,031,931 shares
$8,317,364
Significance 6/10

Chief insider Gadicke sold 1,031,931 shares of ITOS at $8.06; stock down 55.9% from 52-week high, company unprofitable.

GADICKE ANSBERT sold 1,031,931 shares at $8.06, reducing holdings by 23.0% from 4,484,728 to 3,452,797 shares. The timing is notable given the stock's substantial decline: ITOS trades at $7.97 versus a 52-week high of $18.09 (down 55.9%), though it has recovered 34.3% over the past 30 days. The company's fundamentals remain challenged—it is unprofitable with net income of $-34,613,000 and zero latest-quarter revenue, despite posting 177.9% annual revenue growth. A material reduction in senior insider holdings at a depressed valuation warrants investor scrutiny of the company's runway and near-term catalysts, particularly given the unprofitable operating status and the timing of this large stake reduction.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access